Overall market sentiment has been down on Ocuphire Pharma Inc (OCUP) stock lately. OCUP receives a Bearish rating from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.
Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive.
InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.
Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .
What's Happening With OCUP Stock Today?
Ocuphire Pharma Inc (OCUP) stock has fallen -7.64% while the S&P 500 is up 0.96% as of 1:14 PM on Thursday, Apr 15. OCUP is lower by -$0.37 from the previous closing price of $4.91 on volume of 275,482 shares. Over the past year the S&P 500 has risen 46.32% while OCUP is lower by -38.65%. OCUP lost -$5.28 per share in the over the last 12 months.
To see the top 5 stocks in the Biotechnology industry click here.
More About Ocuphire Pharma Inc
Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.
Click Here to get the full Stock Score Report on Ocuphire Pharma Inc (OCUP) Stock.
